Sera Prognostics Inc (SERA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sera Prognostics Inc (SERA) has a cash flow conversion efficiency ratio of -0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.77 Million) by net assets ($67.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sera Prognostics Inc (SERA) balance sheet quality index to measure how much of total assets are equity-financed.
Sera Prognostics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Sera Prognostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sera Prognostics Inc (SERA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Sera Prognostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sera Prognostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Data Centre Group
AU:GDC
|
0.644x |
|
Unitronics
TA:UNIT
|
0.153x |
|
Quality Construction Products Public Company Limited
BK:Q-CON
|
0.032x |
|
Lloyds Engineering Works Limited
NSE:LLOYDSENGG
|
-0.224x |
|
IBU tec advanced materials AG
XETRA:IBU
|
0.255x |
|
NOMAD Power Solutions, Inc.
NASDAQ:NMAD
|
-0.200x |
|
Freeman Gold Corp
V:FMAN
|
-0.019x |
|
New Horizon Aircraft Ltd
NASDAQ:HOVR
|
-0.482x |
Annual Cash Flow Conversion Efficiency for Sera Prognostics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Sera Prognostics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see SERA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $75.41 Million | $-25.62 Million | -0.340x | -14.48% |
| 2024-12-31 | $47.80 Million | $-14.19 Million | -0.297x | +23.41% |
| 2023-12-31 | $70.16 Million | $-27.19 Million | -0.388x | -10.79% |
| 2022-12-31 | $98.94 Million | $-34.61 Million | -0.350x | -53.21% |
| 2021-12-31 | $138.56 Million | $-31.64 Million | -0.228x | +96.02% |
| 2020-12-31 | $2.94 Million | $-16.87 Million | -5.737x | -225.29% |
| 2019-12-31 | $10.96 Million | $-19.32 Million | -1.764x | -- |
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of… Read more